NCT02414334已完成不适用
Immediate Versus Delayed Stereotactic Ablative Radiotherapy (SABR) for Patients With Pulmonary Oligometastases From Colorectal Cancer: SABR SCAN Trial A Randomised Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
Rationale:
SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer. High efficacy in terms of local control of metastatic lesions treated has been shown. Nevertheless, the precise effect of SABR upon progression-free- and overall survival in these patients is unknown. To further evaluate and develop local treatment options in metastatic disease, more information is necessary regarding the impact upon - and the pattern of - disease progression of local treatment options such as SABR.
Objective:
To determine the effect upon progression free survival and upon tumorload relative to baseline, both at one year after randomisation of immediate SABR versus delayed SABR (a scan-and-personalise policy). Secondarily, patterns of progression, patient-reported symptoms and quality of life will be monitored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •WHO-Performance status (WHO-PS) 0 - 1
- •Patients with 1 to 3 lung metastases between 8 mm and 3 cm each, from colorectal cancer. Resection has been considered at a multidisciplinary conference but was not recommended or has been refused by the patient.
- •Possibility to define target lesions that fulfil the following criteria:
- •No lesion larger than 3 cm;
- •Not more than 3 metastases ≥ 8 mm in total (lesions smaller than 8 mm in diameter are NOT counted and will NOT be irradiated);
- •No prior radiotherapy (SABR or other) within about 2 cm from target lesions (i.e., the distance between prior planning-target-volume (PTV) to actual intended PTV is more than 2 cm AND dose distribution of former radiation permits SABR).
- •Primary tumour has been completely removed surgically.
- •Metastases outside target organs (e.g. liver metastases or other) are radically treated locally (resection, radiofrequency ablation (RFA), microwave ablation (MWA), stereotactic radiotherapy, or other). Earlier resected or ablated (SABR, RFA, MWA) metastases to lung, liver, or other organ form no exclusion criterion. Brain metastases should be completely resected or treated with stereotactic radiosurgery. Bone metastases should be resected or treated with high dose radiotherapy (equivalent of > 40 Gy) and be asymptomatic.
- •Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating.
- •Proficiency in the Dutch language so that quality-of-life questionnaires can be completed in Dutch and absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •Before patient randomisation, informed consent must be given according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) of the European Union (EU) in accordance with good clinical practice (GCP), and national/local regulations.
排除标准
- •Any clinical symptoms possibly or certainly caused by index lungmetastases
- •Physical inability to undergo stereotactic radiotherapy (e.g., serious shoulder stiffness)
- •Any uncontrolled malignancy other than index colorectal cancer
- •Other malignancy within recent two years, even if completely under control (under control = no evidence of disease)
- •Failure to comply with any of the inclusion criteria
结局指标
主要结局
Progression free survival (PFS)
时间窗: 12 months after randomisation
次要结局
- Time to failure of local strategy (TFLS): failure = death or progressive disease NOT amenable to local treatment(when it occurs)
- Relative change of tumourload expressed as volume of all tumour at one year divided by volume of all tumour at time of randomisation;(12 months after randomisation)
- Progression of lesions other than target lesions as measured by CT(12 months after randomisation)
- Progression of target lesions as measured by CT(12 months after randomisation)
- Health-related quality of life profile(Baseline; 3 months after randomisation and at 6, 9, 12, 15, 18, 21 and 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)Metastatic TumorsNCT01446744Lawson Health Research Institute99
招募中
不适用
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/ProgressionOligometastatic DiseaseOligoprogressionToxicity Due to RadiotherapyQuality of LifeNCT05784428Robert Olson598
撤回
2 期
Stereotactic ablative radiotherapy (SABR) after systemic antineoplastic treatment for patients with unresectable oligometastases (lung; liver; adrenal glands) from solid tumours: SARASTRO Trial (Stereotactic Ablative Radiotherapy After Systemic TReatment for Oligometastases) A randomised phase II trialmetastasesspread out cancer10027476NL-OMON37714niversitair Medisch Centrum Groningen80
进行中（未招募）
不适用
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) CancerMetastatic TumorsNCT03862911British Columbia Cancer Agency330
进行中（未招募）
2 期
High dose Radiation therapy to eradicate early metastatic prostate cancer as an alternative to hormone or chemotherapy: a prospective phase II studyProstate CancerACTRN12618000566235Integrated Clinical Oncology Network Pty Ltd (ICON)208